Cocrystal Pharma extends Phase 2a flu study due to low infection rate, data uninterpretable

Cocrystal Pharma, Inc.

No SAEs or drug-related discontinuations in Phase 2a study of oral PB2 inhibitor CC-42344.
Low infectivity of H3N2 challenge strain made virology data uninterpretable; enrollment to be extended.
Company plans to submit protocol amendment to UK MHRA to extend enrollment and ensure adequate infection rates.
CC-42344 showed favorable safety/tolerability, but low infection rate hindered antiviral data analysis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.